Research Links

Proneuron Biotechnologies, Inc. and Craig Hospital announced that enrollment in Proneuron's IND Phase II trial of ProCord is now open to patients at Craig Hospital in Denver, Colorado. Based in Israel, Proneuron is a leader in the development of treatments for patients with spinal cord injuries and other acute and chronic disorders of the central nervous system (CNS). Proneuron's processing Cell Center at Craig is the first U.S. site that will test ProCord, which consists of autologous activated macrophage therapy for a randomized controlled trial for patients with acute complete spinal cord injury (SCI) within 14 days of injury. The trial commenced at Sheba Medical Center in Tel Hashomer, Israel, in September 2003. Following the necessary approvals, three additional sites located in the US will also study this experimental procedure including: the Mount Sinai Medical Center in NYC; Kessler Institute for Rehabilitation in West Orange, NJ and Shepherd Center in Atlanta, GA. This is the first step in implementing Proneuron's test of ProCord at multiple geographic clinical sites in their goal to commercialize operations in North America. "We are honored to collaborate with Craig Hospital, one of the top treatment centers in the world for spinal cord injury. We have established a working relationship together in the follow-up rehabilitation of some of the patients who participated in the Phase I trial. It is our hope that our newly established ability to offer our experimental treatment to patients in the U.S. will help us to better serve the patient population in the Americas," said Proneuron's V.P. of Clinical Development Dr. David Snyder. For Patient, Immediate Family of Patient and/or Physician inquiries: 24 hour a day Patient Recruitment Center: Email: clinical.trial@proneuron.com Telephone: 1 866 539 0767

(U.S. toll free) or 1 506 652 3486. Fax: 1 866-214-7078 . Callers outside of the U.S., please use standard international dialing code.

http://www.israel21c.org/bin/en.jsp?enPage=BlankPage&enDisplay=view&enDispWhat=Zone&enDisp

Who=InThePress&enZone=InThePress&Date=12/8/03%2011:35%20PM